Veralice Meireles Sales de Bruin

Dr. Veralice Meireles Sales de Bruin


Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 1995 in Brain
Verified
Journal Article
Closed access
PDF file
SDS. E. Daniel
S. E. Daniel
VBVeralice Meireles Sales de Bruin
Veralice Meireles Sales de Bruin
ALA. J. Lees
A. J. Lees
Seventeen patients with a progressive bradykinetic syndrome and post-mortem findings of neurofibrillary degeneration in cerebral cortex, subcortical nuclei and brainstem were studied. Seven fulfilled currently accepted clinical diagnostic criteria for Steele-Richardson-Olszewski syndrome, whereas the remainder who lacked supranuclear gaze palsy had alternative clinical diagnoses (idiopathic Parkinson's disease, six cases; cerebrovascular disease, two cases; Parkinson's syndrome, one case; Alzheimer's disease, one case). The clinical and pathological findings of the two groups were compared in an attempt to better define the spectrum of Steele-Richardson-Olszewski disease.

16 February 2012 in Sleep and Breathing
Verified
Journal Article
Closed access
PDF file
DNDeuzilane M. Nunes
Deuzilane M. Nunes
VBVeralice Meireles Sales de Bruin
Veralice Meireles Sales de Bruin
FLFernando M. Louzada
Fernando M. Louzada
CPCarina A. T. Peixoto
Carina A. T. Peixoto
ACAntônio G. M. Cavalcante
Antônio G. M. Cavalcante
PBPedro F. C. de Bruin
Pedro F. C. de Bruin

1 January 2016 in The Canadian Journal of Psychiatry
Verified
Journal Article
Open access
PDF file
MMMatias Carvalho Aguiar Melo
Matias Carvalho Aguiar Melo
FMFrancisco das Chagas Medeiros
Francisco das Chagas Medeiros
VBVeralice Meireles Sales de Bruin
Veralice Meireles Sales de Bruin
JSJosé Abraão Pinheiro Santana
José Abraão Pinheiro Santana
ALAlexandre Bastos Lima
Alexandre Bastos Lima
EDElizabeth De Francesco Daher
Elizabeth De Francesco Daher
Objective: Medical residency programs are traditionally known for long working hours, which can be associated with a poor quality of sleep and daytime sleepiness. However, few studies have focused on this theme. Our objective was to investigate sleep quality, daytime sleepiness, and their relation with anxiety, social phobia, and depressive symptoms. Methods: This cross-sectional observational study involved 59 psychiatry residents. The Pittsburgh Sleep Quality Index (PSQI) and the Epworth Sleepiness Scale (ESS) were used to measure the quality of sleep and excessive daytime sleepiness ([EDS] and ESS > 10), respectively. Results: Among the 59 psychiatry residents, 59.3% had poor sleep quality (PSQI > 5) and 28.8% had EDS. Poor sleep quality was associated with higher EDS ( P = 0.03) and the year of residency program ( P = 0.03). Only 20% of residents with poor sleep had consulted at least once for sleep problems; 54.2% had used medications for sleep; and 16.9% were using medications at the time of interview. Only 30% obtained medication during medical consultations. Poor sleep was associated with irregular sleep hours ( P = 0.001) and long periods lying down without sleep ( P = 0.03). Poor sleep quality was also associated with high scores of anxiety symptoms ( P < 0.001) and social phobia symptoms ( P = 0.02). Conclusion: Psychiatry residents frequently have poor sleep quality and EDS. Considering that sleep disorders can affect quality of life, predispose to metabolic syndrome, and be associated with worse performance at work, attention to this clinical problem is needed.

23 November 2007 in Neurogastroenterology & Motility
Verified
Journal Article
Closed access
PDF file
FSF. P. Da Silva‐Júnior
F. P. Da Silva‐Júnior
ACA. E. A. B. Carrasco
A. E. A. B. Carrasco
AMA. M. Da Silva Mendes
A. M. Da Silva Mendes
Agnaldo José LopesAgnaldo José Lopes
Agnaldo José Lopes
MSM. A. Nobre E Souza
M. A. Nobre E Souza
VBVeralice Meireles Sales de Bruin
Veralice Meireles Sales de Bruin

27 August 2025 in Clinical Bioenergetics
Verified
Journal Article
Open access
PDF file
PNPaulo Iury Gomes Nunes
Paulo Iury Gomes Nunes
Stephen Rathinaraj BenjaminStephen Rathinaraj Benjamin
Stephen Rathinaraj Benjamin
RBRafaela de Sousa Brito
Rafaela de Sousa Brito
MAMateus Rodrigues De Aguiar
Mateus Rodrigues De Aguiar
LNLorena Bizarria Neves
Lorena Bizarria Neves
VBVeralice Meireles Sales de Bruin
Veralice Meireles Sales de Bruin
Psychiatric disorders such as major depressive disorder, bipolar disorder, and schizophrenia are now recognized as complex systemic conditions in which mitochondrial dysfunction and oxidative stress are key contributors to their pathophysiology. Mitochondria, beyond their role in ATP synthesis, are critical for calcium regulation, immune responses, and apoptosis, and their impairment affects brain function. This review examines current evidence from transcriptomics, metabolomics, neuroimaging, and preclinical studies, which consistently show disruptions in oxidative phosphorylation, mitochondrial fragmentation, altered mitochondrial DNA, and heightened inflammatory activity across these disorders. We integrate recent advances with the understanding of mitochondrial bioenergetics in the brain, the contribution of redox imbalance to neural dysfunction, the crosstalk between mitochondria and immune mechanisms, and the relevance of these processes to clinical symptoms. Furthermore, we highlight the promise of bioenergetic biomarkers and emerging interventions targeting mitochondrial pathways, including antioxidants, AMPK-SIRT1-PGC-1α axis modulators, physical exercise, and mitoprotective agents. Peripheral metabolic signatures and neuroimaging modalities are also discussed as tools for diagnostic refinement and individualized therapeutic approaches. These insights underscore the centrality of mitochondrial health in psychiatric disease and support the development of precision psychiatry grounded in metabolic phenotyping.

1 November 2012 in The Brazilian Journal of Infectious Diseases
Verified
Journal Article
Open access
ALAlexandre Liborio
Alexandre Liborio
GJGeraldo Silva Junior
Geraldo Silva Junior
CSCarolina G.C.H. Silva
Carolina G.C.H. Silva
FFFrancisco J.C. Lima Filho
Francisco J.C. Lima Filho
ANAdalberto Studart Neto
Adalberto Studart Neto
EDElizabeth F. Daher
Elizabeth F. Daher
There are no reports on hyponatremia and acute kidney injury (AKI) involved in the course of HIV-related toxoplasmic encephalitis (TE). The main objective of this study was to describe the occurrence of hyponatremia and its relationship with AKI and mortality in HIV-related toxoplasmic encephalitis (TE). This was a retrospective cohort study on patients with HIV-related TE. AKI was considered only when the RIFLE (risk, injury, failure, loss, end-stage) criterion was met, after the patient was admitted. A total of 92 patients were included, with a mean age of 36 ± 9 years. Hyponatremia at admission was observed in 43 patients (46.7%), with AKI developing in 25 (27.1%) patients during their hospitalization. Sulfadiazine was the treatment of choice in 81% of the cases. Death occurred in 13 cases (14.1%). Low serum sodium level correlated directly with AKI and mortality. Male gender (OR 7.89, 95% CI 1.22-50.90, p = 0.03) and hyponatremia at admission (OR 4.73, 95% CI 1.22-18.30, p = 0.02) were predictors for AKI. Independent risk factors for death were AKI (OR 8.3, 95% CI 1.4-48.2, p < 0.0001) and hyponatremia (OR 9.9, 95% CI 1.2-96.3, p < 0.0001). AKI and hyponatremia are frequent in TE. Hyponatremia on admission is highly associated with AKI and mortality.